Literature DB >> 21718818

Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy.

Ming Liu1, Gening Jiang, Wenxin He, Peng Zhang, Nan Song.   

Abstract

First-line therapy with gefitinib prolongs progression-free survival and improves quality of life among selected patients with non-small cell lung cancer. Selected locally advanced patients may derive benefit from surgical resection after gefitinib therapy. Further clinical trials are needed to evaluate the role of gefitinib therapy followed by surgical resection.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21718818     DOI： 10.1016/j.athoracsur.2011.02.021

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN： 0003-4975            Impact factor:   4.330


  4 in total

1.  Radical surgical resection after neoadjuvant targeted therapy in non-small cell lung cancer: a single-center retrospective study of 6 cases.

Authors:  Zhenyang Zhang; Jiangbo Lin; Shuai Peng; Wenwei Lin; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

2.  Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?

Authors:  D Marquez-Medina; A Chachoua; A Martin-Marco; A M Desai; V Garcia-Reglero; A Salud-Salvia; F Muggia
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

3.  Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report.

Authors:  A López-González; E Almagro; C Salas; A Varela; M Provencio
Journal:  Respir Med Case Rep       Date:  2013-04-24

Review 4.  Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.

Authors:  Yoko Yamamoto; Ken Kodama; Tomohiro Maniwa; Masashi Takeda
Journal:  J Cardiothorac Surg       Date:  2017-11-23       Impact factor: 1.637
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.